# Capricor Therapeutics, Inc.

**CAPR**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001133869


# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $355.9M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, short runway, thin data, dege...<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Mar 17, 2026<br>224 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $5.74<br>2026-10-26; market equity $333.7M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 17, 2026*

Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy ("DMD"), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 32.5** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (13.4%) | (6.6%) | | 32.5 | 805 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 17.0** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | 6.86 | (0.33) | | 14.8 | 751 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *interest expense must exceed $100,000* | | | | | | |
| Current ratio | 9.01x | 2.94x | | 19.1 | 832 | 2025-12-31 |
| **Growth and financing, sleeve percentile 34.0** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *current value must be positive and the base must exceed $100,000* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | 92.2% | 2.1% | | 2.6 | 697 | 2025-12-31 |
| Net share issuance, one year | 25.9% | 2.5% | | 65.4 | 634 | 2026-03-16 |

## Warnings

*4 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 25.9% |
| Short runway | cash runway is 2.4 months |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-10-26 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 37.4% | 7.7% | 70 |
| Distance from 52-week high | (83.8%) | (31.2%) | 7 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (21.8%) | (1.0%) | 23 |
| Book value to price | 0.74 | 0.28 | 79 |
| Sales to price | 0.00 | 0.30 | 0 |
| Composite equity issuance, five years | 93.6% | 20.5% | 76 |
| Relative strength against the sector, log excess return | 0.11 | (0.14) | 70 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $20.9M |
| Operating cash flow, four quarters | -$104.0M |
| Months of runway | 2.4 |
| Days since last periodic filing | 74 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $23.6M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$105.0M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$69.8M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 3 | assets | us-gaap:Assets | $355.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 4 | assets | us-gaap:Assets | $170.5M | 2024-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 5 | current assets | us-gaap:AssetsCurrent | $322.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $35.8M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$304.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$108.1M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 9 | book equity | us-gaap:StockholdersEquity | $305.8M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 10 | liabilities | us-gaap:Liabilities | $50.2M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$15.3M | 2018-12-31 | 2020-03-27 | 10-K | 20-039272 |
| 12 | interest expense | us-gaap:InterestExpense | $0 | 2018-12-31 | 2019-03-29 | 10-K | 19-016787 |
| 13 | revenue | us-gaap:Revenues | $0 | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 14 | revenue | us-gaap:Revenues | $22.3M | 2024-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 15 | revenue | us-gaap:Revenues | $25.2M | 2023-12-31 | 2025-03-26 | 10-K | 25-003707 |
| 16 | revenue | us-gaap:Revenues | $2.6M | 2022-12-31 | 2024-03-11 | 10-K | 24-002861 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$40.0M | 2024-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.2M | 2024-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$25.6M | 2023-12-31 | 2025-03-26 | 10-K | 25-003707 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.3M | 2023-12-31 | 2025-03-26 | 10-K | 25-003707 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $4.9M | 2022-12-31 | 2024-03-11 | 10-K | 24-002861 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.0M | 2022-12-31 | 2024-03-11 | 10-K | 24-002861 |
| 24 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $1.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 25 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$105.0M | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 26 | income tax | us-gaap:IncomeTaxExpenseBenefit | $1,600 | 2025-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 27 | current assets | us-gaap:AssetsCurrent | $163.4M | 2024-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 28 | current liabilities | us-gaap:LiabilitiesCurrent | $21.0M | 2024-12-31 | 2026-03-17 | 10-K | 26-029580 |
| 29 | assets | us-gaap:Assets | $58.7M | 2023-12-31 | 2025-03-26 | 10-K | 25-003707 |
| 30 | assets | us-gaap:Assets | $50.1M | 2022-12-31 | 2024-03-11 | 10-K | 24-002861 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 57,510,635 | 2026-03-16 | 2026-03-17 | 10-K | 26-029580 |
| 32 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 45,676,202 | 2025-03-24 | 2025-03-26 | 10-K | 25-003707 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.